Viridian Therapeutics Inc is a biotechnology business based in the US. Viridian Therapeutics shares (VRDN) are listed on the NASDAQ and all prices are listed in US Dollars. Viridian Therapeutics employs 26 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $19.66 |
|---|---|
| 52-week range | $10.44 - $25.19 |
| 50-day moving average | $19.54 |
| 200-day moving average | $16.93 |
| Wall St. target price | $35.25 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-19.21 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $19.66 from 2022-01-19
| 1 week (2022-01-14) | -1.70% |
|---|---|
| 1 month (2021-12-21) | -4.10% |
| 3 months (2021-10-21) | 17.80% |
| 6 months (2021-07-21) | 16.26% |
| 1 year (2021-01-21) | -2.04% |
|---|---|
| 2 years (2020-01-21) | 3,140.48% |
| 3 years (2019-01-18) | 550.99% |
| 5 years (2017-01-20) | 96.80% |
| Revenue TTM | $2.8 million |
|---|---|
| Gross profit TTM | $-26,954,000 |
| Return on assets TTM | -34.98% |
| Return on equity TTM | -125.17% |
| Profit margin | 0% |
| Book value | $2.23 |
| Market capitalisation | $412.9 million |
TTM: trailing 12 months
We're not expecting Viridian Therapeutics to pay a dividend over the next 12 months.
Viridian Therapeutics's shares were split on a 1:15 basis on 12 November 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Viridian Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Viridian Therapeutics shares which in turn could have impacted Viridian Therapeutics's share price.
Over the last 12 months, Viridian Therapeutics's shares have ranged in value from as little as $10.44 up to $25.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viridian Therapeutics's is 1.0806. This would suggest that Viridian Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Viridian Therapeutics, Inc. , a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.